Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer
2019 ◽
2020 ◽
2016 ◽
Vol 4
(4)
◽
pp. 648-654
◽
2020 ◽
2015 ◽
Vol 6
(6)
◽
pp. 220
◽